Nombre del producto:(3R)-3-aminopentanenitrile

IUPAC Name:(3R)-3-aminopentanenitrile

CAS:400090-60-0
Fórmula molecular:C5H10N2
Pureza:95%+
Número de catálogo:CM604922
Peso molecular:98.15

Unidad de embalaje Stock disponible Precio($) Cantidad

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :400090-60-0
Fórmula molecular:C5H10N2
Punto de fusión:-
Código de sonrisas:CC[C@@H](N)CC#N
Densidad:
Número de catálogo:CM604922
Peso molecular:98.15
Punto de ebullición:
Nº Mdl:MFCD08703198
Almacenamiento:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Obicetrapib
The elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), and heterozygous familial hypercholesterolemia (HeFH). Cholesteryl ester transfer protein (CETP) transports cholesterol from good high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C). NewAmsterdam’s Obicetrapib is a novel, selective CETP inhibitor to address the limitations of current treatments.
Obicetrapib is under investigation in phase III clinical trials as a monotherapy product, and in phase II studies as a fixed dose combination with Ezetimibe.

Related Products